Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension
Marc A Benninga, Sunny Z Hussain, Manu R Sood, Samuel Nurko, Paul Hyman, Robert A Clifford, Molly O'Gorman, Taryn Losch-Beridon, Shadreck Mareya, Peter Lichtlen, Carlo Di Lorenzo, Marc A Benninga, Sunny Z Hussain, Manu R Sood, Samuel Nurko, Paul Hyman, Robert A Clifford, Molly O'Gorman, Taryn Losch-Beridon, Shadreck Mareya, Peter Lichtlen, Carlo Di Lorenzo
Abstract
Background & aims: Pediatric functional constipation (PFC) is a common problem in children that causes distress and presents treatment challenges to health care professionals. We conducted a randomized, placebo-controlled trial (study 1) in patients with PFC (6-17 years of age) to evaluate the efficacy and safety of lubiprostone, followed by an open-label extension for those who completed the placebo-controlled phase (study 2).
Methods: Study 1 (NCT02042183) was a phase 3, multicenter, randomized, double-blind, placebo-controlled, 12-week study evaluating the efficacy and safety of lubiprostone 12 μg twice daily (BID) and 24 μg BID. Study 2 (NCT02138136) was a phase 3, long-term, open-label extension of study 1. In both studies, lubiprostone doses were based on patients' weight. Efficacy was assessed solely based on study 1, with a primary endpoint of overall spontaneous bowel movement (SBM) response (increase of ≥1 SBM/wk vs baseline and ≥3 SBMs/wk for ≥9 weeks, including 3 of the final 4 weeks).
Results: 606 patients were randomized to treatment (placebo: n = 202; lubiprostone: n = 404) in study 1. No statistically significant difference in overall SBM response rate was observed between the lubiprostone and placebo groups (18.5% vs 14.4%; P = .2245). Both the 12-μg BID and 24-μg BID doses of lubiprostone were well tolerated in the double-blind and extension phases, with a safety profile consistent with that seen in adult studies.
Conclusions: Lubiprostone did not demonstrate statistically significant effectiveness over placebo in children and adolescents with PFC but did demonstrate a safety profile similar to that in adults. (ClinicalTrials.gov: Number: NCT02042183; Number: NCT02138136).
Keywords: Clinical Trial; Defecation; Incontinence; Stools.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed